Acute Myeloid Leukemia (AML) is the most common type of leukemia diagnosed in adults, representing roughly 32% of all adult leukemia cases in the United States. Each year, approximately 20,800 new cases are diagnosed, with a median age at diagnosis of 68. If you’re researching whether AML is truly the most common leukemia — yes, among adults it is, and it’s also one of the most aggressive.
That said, the leukemia landscape is a bit more nuanced than a single ranking. Chronic lymphocytic leukemia (CLL) is actually the most common leukemia overall when you include slow-growing (chronic) types that accumulate over years. But when we’re talking about acute leukemias — the ones that hit fast and demand immediate treatment — AML dominates the adult population. In children, acute lymphoblastic leukemia (ALL) is far more common.
How AML Compares to Other Leukemia Types
| Leukemia Type | New U.S. Cases/Year (approx.) | Median Age at Diagnosis | 5-Year Survival Rate | Most Affected Group |
|---|---|---|---|---|
| AML | ~20,800 | 68 | ~31% | Adults 65+ |
| CLL | ~20,700 | 72 | ~88% | Older adults |
| CML | ~9,000 | 65 | ~70% | Adults 50+ |
| ALL | ~6,500 | 15 (bimodal) | ~72% | Children 2–5; adults 50+ |
Notice the 5-year survival rate for AML: roughly 31%. That number climbs significantly for younger patients (around 45–50% for those under 60) but drops below 15% for patients over 65. This stark difference drives many of the treatment decisions oncologists face daily.
What Actually Happens in AML
In AML, a mutation occurs in a myeloid precursor cell in the bone marrow — the factory that produces your red blood cells, white blood cells, and platelets. Instead of maturing into functional cells, these precursors get stuck as immature myeloblasts and start multiplying uncontrollably.
The diagnostic threshold is specific: AML is defined by ≥20% myeloblasts in the bone marrow or peripheral blood (per WHO criteria). These blasts crowd out healthy cells, which is why patients develop anemia, infections, and bleeding — the marrow simply can’t produce enough normal cells anymore.
Symptoms That Bring Patients to the Doctor
AML tends to announce itself quickly, often over days to weeks rather than months. The symptoms map directly to which blood cell lines are being suppressed:
- Low red blood cells (anemia): Crushing fatigue, shortness of breath with minimal exertion, pale skin
- Low platelets (thrombocytopenia): Easy bruising, petechiae (tiny red dots on skin), nosebleeds, bleeding gums
- Low functional white blood cells (neutropenia): Recurrent or severe infections, fevers that won’t resolve
- Leukemia cell infiltration: Bone pain (especially sternum and long bones), swollen gums, skin nodules
One presentation that warrants an immediate ER visit: disseminated intravascular coagulation (DIC), a dangerous clotting disorder seen particularly with the APL (Promyelocytic Leukemia: From Definition to…”>acute promyelocytic leukemia) subtype. Uncontrolled bleeding or clotting with a new AML diagnosis is a medical emergency.
Causes and Risk Factors
Most AML cases arise from acquired genetic mutations — not inherited ones. The most commonly mutated genes include FLT3 (present in ~30% of cases), NPM1 (~30%), DNMT3A (~25%), and IDH1/IDH2 (~15–20%). These mutations matter because they increasingly guide treatment selection.
Established risk factors include:
- Age over 60 — risk increases substantially with each decade
- Prior chemotherapy or radiation — therapy-related AML accounts for 10–15% of cases
- Antecedent blood disorders — especially myelodysplastic syndromes (MDS) and myeloproliferative neoplasms
- Smoking — associated with a 40% increased risk of AML
- Benzene exposure — well-documented occupational risk factor
- Genetic syndromes — Down syndrome carries a 10–20x increased AML risk in children
How AML Is Diagnosed
Diagnosis typically starts with a complete blood count (CBC) that looks wrong — often very high white blood cell counts with circulating blasts, or paradoxically low counts across all cell lines (pancytopenia). A peripheral blood smear may show blasts with Auer rods, crystallized granules that are essentially pathognomonic for AML.
Confirmation requires a bone marrow biopsy with aspirate. From that sample, three additional layers of testing refine the diagnosis:
- Flow cytometry: Identifies surface markers on the leukemia cells (CD33, CD117, MPO positivity typical of AML)
- Cytogenetics: Detects chromosomal abnormalities — t(15;17) in APL, t(8;21) and inv(16) are favorable-risk abnormalities
- Molecular testing: Identifies specific gene mutations (FLT3, NPM1, CEBPA, TP53) that determine prognosis and targeted therapy options
This molecular profiling has transformed AML from a single disease into dozens of subtypes, each with different expected outcomes and treatment strategies.
AML Treatment: A Two-Phase Approach
Phase 1: Induction Therapy
The classic induction regimen — nicknamed “7+3” — combines 7 days of continuous cytarabine infusion with 3 days of an anthracycline (usually daunorubicin or idarubicin). This protocol has been the backbone of AML treatment for over 40 years, and it achieves complete remission in 60–80% of patients under 60.
For older or less fit patients, newer options include venetoclax combined with azacitidine, which has dramatically improved outcomes for patients who can’t tolerate intensive chemotherapy. This combination achieved a median overall survival of 14.7 months versus 9.6 months for azacitidine alone in the landmark VIALE-A trial.
Phase 2: Consolidation and Beyond
Achieving remission is only half the battle. Without consolidation therapy, relapse is nearly certain. Options include:
- High-dose cytarabine cycles — standard for favorable-risk AML
- Allogeneic stem cell transplant — the only potentially curative option for intermediate and adverse-risk AML
- Targeted therapies — FLT3 inhibitors (midostaurin, gilteritinib), IDH inhibitors (ivosidenib, enasidenib) for patients with specific mutations
When to See a Doctor
Seek medical attention promptly — not in a few weeks, but within days — if you experience:
- Unexplained fatigue that doesn’t improve with rest
- Recurrent fevers or infections without a clear cause
- Unusual bruising, bleeding gums, or petechiae
- A CBC showing blasts in the peripheral blood — this warrants same-day hematology referral
AML progresses rapidly. A delay of even 1–2 weeks can mean the difference between a manageable and a critical presentation.
Frequently Asked Questions
Is AML really the most common type of leukemia?
Among acute leukemias in adults, yes — AML is by far the most common. When including chronic leukemias, CLL has comparable incidence numbers. But AML causes more leukemia-related deaths annually (~11,000 in the U.S.) than any other type due to its aggressive behavior and lower overall survival rate.
Can you survive AML?
Absolutely, though outcomes vary enormously by age, molecular subtype, and fitness for treatment. Young patients with favorable-risk genetics (like NPM1-mutated without FLT3-ITD) can have 5-year survival rates exceeding 60%. APL, a specific AML subtype, now has cure rates above 90% with ATRA-based therapy. Older patients with adverse-risk cytogenetics face much tougher odds, with 5-year survival rates below 10%.
What does AML treatment feel like?
Intensive induction chemotherapy typically requires a 4–6 week hospital stay. Patients experience profound fatigue, nausea, hair loss, mouth sores, and prolonged periods of dangerously low blood counts requiring transfusions and antibiotics. Newer lower-intensity regimens (like venetoclax + azacitidine) are generally given outpatient and are better tolerated, though they still carry significant infection risk.
Is AML hereditary?
In the vast majority of cases, no. Fewer than 5% of AML cases have a clear hereditary component. However, certain inherited conditions — including Li-Fraumeni syndrome, Fanconi anemia, and familial platelet disorder with predisposition to AML (caused by RUNX1 mutations) — do significantly increase risk. If multiple family members have been diagnosed with blood cancers, genetic counseling may be appropriate.
What’s the difference between AML and ALL?
Both are acute leukemias, but they originate from different cell lines. AML arises from myeloid precursors, while ALL comes from lymphoid precursors. ALL is the most common cancer in children (peaking at ages 2–5), while AML predominates in older adults. Treatment approaches, drug sensitivities, and outcomes differ substantially between the two.
